Global Information
회사소개 | 문의 | 비교리스트

세계의 의도적 혼수/의학적으로 유도된 혼수 시장 기회 분석 및 산업 예측(2021-2030년) : 유형, 용도, 유통경로별

Artificial Coma/Medically Induced Coma Market by Drug Type, Application, and Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021--2030

리서치사 Allied Market Research
발행일 2021년 12월 상품코드 1059633
페이지 정보 영문 241 Pages 배송안내 2-3일 (영업일 기준)
가격
US $ 4,125 ₩ 5,256,000 Excel (Data Pack) help
DRM(디지털 저작권 관리 시스템) 장착 Excel 파일로, 1명만 이용할 수 있는 라이선스입니다. 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 Excel파일 라이선스 소유자로 한정됩니다.
US $ 6,168 ₩ 7,859,000 PDF (Single User License + Covid impact) help
DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 PDF 라이선스 소유자로 한정됩니다.
US $ 6,929 ₩ 8,828,000 PDF (5-user License) help
DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 5명까지 이용할 수 있는 라이선스입니다. 인쇄는 5회까지 가능하며 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,663 ₩ 13,586,000 PDF (Enterprise User License) help
동일 기업 내의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 의도적 혼수/의학적으로 유도된 혼수 시장 기회 분석 및 산업 예측(2021-2030년) : 유형, 용도, 유통경로별 Artificial Coma/Medically Induced Coma Market by Drug Type, Application, and Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021--2030
발행일 : 2021년 12월 페이지 정보 : 영문 241 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 의도적인 혼수/의학적으로 유도된 혼수 시장 규모는 2020년 6억 4,017만 달러에서 예측기간에는 3.1%의 연평균 복합 성장률(CAGR)로 확대되어 2030년까지 8억 6,863만 달러 규모로 성장할 것으로 예측됩니다.

성형수술, 뇌수술 등의 외과 수술 건수 증가가 환자의 혼수를 유발하기 위한 프로포폴이나 바르비투르산염 등의 약제 사용 급증으로 이어지면서 시장 성장을 가속하고 있습니다. 고령자 인구 증가 또한 시장 성장에 크게 기여하고 있습니다. 한편, 의도적인 혼수/의학적으로 유도된 혼수에 수반하는 부작용, 임신 중인 여성에 관련된 리스크 등의 과제가 예측기간 중 시장 성장을 방해할 것으로 예상됩니다.

세계의 의도적인 혼수/의학적으로 유도된 혼수(Artificial Coma/Medically Induced Coma) 시장을 조사했으며, 시장의 정의와 개요, 시장 영향요인 분석, 시장 규모 추이와 예측, 유형·용도·유통경로·지역/주요 국가 등 각종 구분별 분석, 경쟁 환경, 주요 기업 프로파일 등의 정보를 정리하여 전해드립니다.

목차

제1장 서론

제2장 개요

제3장 시장 구도

  • 시장의 정의와 범위
  • 주요 조사 결과
  • Porter의 산업 분석
  • 주요 기업의 포지셔닝
  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 시장 기회
    • 영향 분석
  • COVID-19 : 영향 분석

제4장 의도적인 혼수/의학적으로 유도된 혼수 시장 : 유형별

  • 개요
  • 프로포폴
  • 바르비투르산염
    • 주요 시장 동향, 성장요인, 기회
    • 시장 규모와 예측 : 지역별
    • 시장 분석 : 국가별

제5장 의도적인 혼수/의학적으로 유도된 혼수 시장 : 용도별

  • 개요
  • 뇌전증 지속상태
  • 뇌졸중
  • 외상성 뇌손상
  • 뇌감염
  • 약물 과다복용
  • 기타
    • 시장 규모와 예측 : 지역별
    • 시장 분석 : 국가별

제6장 의도적인 혼수/의학적으로 유도된 혼수 시장 : 유통경로별

  • 개요
  • 병원 약국
  • 드럭스토어/소매 약국
    • 시장 규모와 예측 : 지역별
    • 시장 분석 : 국가별

제7장 의도적인 혼수/의학적으로 유도된 혼수 시장 : 지역별

  • 개요
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카, 중동 및 아프리카
    • 주요 시장 동향, 성장요인, 기회
    • 의도적인 혼수/의학적으로 유도된 혼수 시장 : 유형별
    • 의도적인 혼수/의학적으로 유도된 혼수 시장 : 용도별
    • 의도적인 혼수/의학적으로 유도된 혼수 시장 : 유통경로별
    • 시장 규모와 예측 : 국가별

제8장 기업 개요

  • ASTRAZENECA PLC
  • B.BRAUN MELSUNGEN AG
  • BAXTER INTERNATIONAL INC.
  • DR. REDDY'S LABORATORY
  • FRESENIUS SE & CO KGAA
  • HIKMA PHARMACEUTICALS
  • PFIZER INC.
  • PIRAMAL GROUP
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • VIATRIS INC.(MYLAN N.V)
LSH 22.03.10

LIST OF TABLES

  • TABLE 01.GLOBAL ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
  • TABLE 02.ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET FOR PROPOFOL, BY REGION, 2020-2030 ($MILLION)
  • TABLE 03.ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET FOR BARBITURATE, BY REGION, 2020-2030 ($MILLION)
  • TABLE 04.GLOBAL ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 05.ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET FOR STATUS EPILEPTICUS , BY REGION, 2020-2030 ($MILLION)
  • TABLE 06.ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET FOR STROKE, BY REGION, 2020-2030 ($MILLION)
  • TABLE 07.ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET FOR TRAUMATIC BRAIN INJURY, BY REGION, 2020-2030 ($MILLION)
  • TABLE 08.ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET FOR BRAIN INFECTION, BY REGION, 2020-2030 ($MILLION)
  • TABLE 09.ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET FOR DRUG OVEREDOSE, 2020-2030 ($MILLION)
  • TABLE 10.ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 11.GLOBAL ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 12.ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET FOR HOSPITAL PHARMACIES, BY REGION, 2020-2030 ($MILLION)
  • TABLE 13.ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET FOR DRUG STORES & RETAIL PHARMACIES, BY REGION, 2020-2030 ($MILLION)
  • TABLE 14.GLOBAL ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 15.NORTH AMERICA ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 16.NORTH AMERICAARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 17.NORTH AMERICAARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 18.NORTH AMERICAARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 19.U.S. ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 20.U.S. ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 21.U.S. ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTIO CHANNEL, 2020-2030 ($MILLION)
  • TABLE 22.CANADA ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 23.CANADA ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 24.CANADA ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 25.MEXICO ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 26.MEXICO ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 27.MEXICO ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY DISTRIBUTION HANNEL, 2020-2030 ($MILLION)
  • TABLE 28.EUROPE ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 29.EUROPE ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 30.EUROPE ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 31.EUROPE ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 32.GERMANY ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 33.GERMANY ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 34.GERMANY ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTON CHANNEL, 2020-2030 ($MILLION)
  • TABLE 35.FRANCE ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 36.FRANCE ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 37.FRANCE ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 38.UK ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 39.UK ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 40.UK ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 41.ITALY ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 42.ITALY ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 43.ITALY ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 44.SPAIN ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 45.SPAIN ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 46.SPAIN ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 47.REST OF EUROPE ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 48.REST OF EUROPE ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 49.REST OF EUROPE ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 50.ASIA-PACIFIC ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 51.ASIA-PACIFIC ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 52.ASIA-PACIFIC ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 53.ASIA-PACIFIC ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 54.JAPAN ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 55.JAPAN ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 56.JAPAN ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 57.CHINA ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 58.CHINA ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 59.CHINA ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 60.AUSTRALIA ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 61.AUSTRALIA ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 62.AUSTRALIA ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 63.INDIA ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 64.INDIA ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 65.SOUTH KOREA ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 66.INDIA ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 67.REST OF ASIA-PACIFIC ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 68.REST OF ASIA-PACIFIC ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 69.REST OF ASIA-PACIFIC ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 70.LAMEA ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 71.LAMEA ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 72.LAMEA ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 73.LAMEA ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 74.BRAZIL ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 75.BRAZIL ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 76.BRAZIL ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 77.SAUDI ARABIA ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 78.SAUDI ARABIA ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 79.SAUDI ARABIA ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 80.SOUTH AFRICA ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 81.SOUTH AFRICA ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 82.SOUTH AFRICA ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 83.REST OF LAMEA ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 84.REST OF LAMEA ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 85.REST OF LAMEA ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 86.ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 87.ASTRAZENECA: OPERATING SEGMENTS
  • TABLE 88.ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 89.ASTRAZENCA:KEY STRATEGIES & DEVELOPMENTS
  • TABLE 90.B. BRAUN:: COMPANY SNAPSHOT
  • TABLE 91.B. BRAUN :OPERATING SEGMENTS
  • TABLE 92.B. BRAUN: PRODUCT PORTFOLIO
  • TABLE 93.BAXTER: COMPANY SNAPSHOT
  • TABLE 94.BAXTER:OPREATING SEGMENTS
  • TABLE 95.BAXTER: PRODUCT PORTFOLIO
  • TABLE 96.REDDY'S:COMPANY SNAPSHOT
  • TABLE 97.REDDY'S: OPERATING SEGMENTS
  • TABLE 98.REDDY'S: PRODUCT PORTFOLIO
  • TABLE 99.REDDY'S : KEY STRATEGIES & DEVELOPMENTS
  • TABLE 100.FRESENIUS : COMPANY SNAPSHOT
  • TABLE 101.FRESENIUS: OPERATING SEGMENTS
  • TABLE 102.FRESENIUS: PRODUCT PORTFOLIO
  • TABLE 103.FRESENIUS : KEY STRATEGIES & DEVELOPMENTS
  • TABLE 104.HIKMA:COMPANY SNAPSHOT
  • TABLE 105.HIKMA:OPERATING SEGMENTS
  • TABLE 106.HIKMA: PRODUCT PORTFOLIO
  • TABLE 107.HIKMA: KEY STATEGIES & DEVELOPMENTS
  • TABLE 108.PFIZER: COMPANY SNAPSHOT
  • TABLE 109.PFIZER: OPERATING SEGMENTS
  • TABLE 110.PFIZER: PRODUCT PORTFOLIO
  • TABLE 111.PIRAMAL: COMPANY SNAPSHOT
  • TABLE 112.PIRAMAL: OPERATING SEGMENTS
  • TABLE 113.PIRAMAL: PRODUCT PORTFOLIO
  • TABLE 114.TEVA: COMPANY SNAPSHOT
  • TABLE 115.TEVA: OPERATING SEGMENTS
  • TABLE 116.TEVA: PRODUCT PORTFOLIO
  • TABLE 117.VIATRIS : COMPANY SNAPSHOT
  • TABLE 118.VIATRIS INC.: OPERATING SEGMENTS
  • TABLE 119.VIATRIS INC: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2020
  • FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2020
  • FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2020
  • FIGURE 06.HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 08.HIGH THREAT OF SUBSTITUTES
  • FIGURE 09.HIGH THREAT OF NEW ENTRANTS
  • FIGURE 10.HIGH INTENSITY OF RIVALRY
  • FIGURE 11.TOP PLAYER POSITIONING, 2020
  • FIGURE 12.IMPACT ANALYSIS
  • FIGURE 13.COMPARATIVE ANALYSIS OF ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET FOR PROPOFOL, BY COUNTRY, 2020-2030 (%)
  • FIGURE 14.COMPARATIVE ANALYSIS OF ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET FOR BARBITURATE, BY COUNTRY, 2020-2030 (%)
  • FIGURE 15.COMPARATIVE ANALYSIS OF ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET FOR STATUS EPILEPTICUS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 16.COMPARATIVE ANALYSIS OF ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET FOR STROKE, BY COUNTRY, 2020-2030 (%)
  • FIGURE 17.COMPARATIVE ANALYSIS OF ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET FOR TRAUMATIC BRAIN INJURY, BY COUNTRY, 2020-2030 (%)
  • FIGURE 18.COMPARATIVE ANALYSIS OF ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET FOR BRAIN INFECTIONS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 19.COMPARATIVE ANALYSIS OF ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET FOR DRUG OVERDOSE, BY COUNTRY, 2020-2030 (%)
  • FIGURE 20.COMPARATIVE ANALYSIS OF ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET FOR OTHERS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 21.COMPARATIVE ANALYSIS OF ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2020-2030 (%)
  • FIGURE 22.COMPARATIVE ANALYSIS OF ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET FOR DRUG STORES & RETAIL PHARMACIES, BY COUNTRY, 2020-2030 (%)
  • FIGURE 23.ASTRAZENECA: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 24.ASTRAZENECA: REVENUE SHARE BY REGION (%)
  • FIGURE 25.B. BRAUN: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 26.BAXTER: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 27.BAXTER: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 28.BAXTER: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 29.REDDY'S: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 30.REDDY'S: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 31.FRESENIUS: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 32.FRESENIUS: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 33.FRESENIUS: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 34.HIKMAN: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 35.HIKMA: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 36.PFIZER: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 37.PFIZER: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 38.PIRAMAL: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 39.TEVA: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 40.TEVA: REVENUE SHARE BY SEGMENT 2020 (%)
  • FIGURE 41.TEVA: REVENUE SHARE, BY REGION 2020 (%)
  • FIGURE 42.VIATRIS : NET SALES, 2018-2020 ($MILLION)
  • FIGURE 43.VIATRIS: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 44.VIATRIS: REVENUE SHARE BY REGION, 2020(%)

The global artificial coma/medically induced coma market was valued at $640.17 million in 2020, and is projected to reach $868.63 million by 2030, registering a CAGR of 3.1%.

Artificial coma/medically induced coma is a state of unconsciousness. During this condition, a person does not respond to environment. The person is alive and looks like he/she is sleeping. An artificial coma effectively shuts down the patient's brain activity. It is a deep, but reversible unconsciousness which doctors purposely induce. The main aim of medically induced coma is to reach at the level of sedation, which is called 'burst suppression'. The brain is completely quite in that state for some time. Doctors use tactic for the treatment of those who suffered from a serious traumatic brain injury. Before undergoing the surgical procedure, doctors give certain medications to patient for the management of pain.

There are couple of options to inducing coma for medical reasons such as during surgical procedure of stroke, status epilepticus and other brain infections. High pressure on brain caused swelling and it stops the flow of oxygen to the brain leads the damage of the brain tissue. Reducing the electrical activity of the brain and induced coma can reduce the swelling and inflammation of the brain. The global artificial coma/medically induced coma market is majorly driven by an alarming increase in the prevalence of traumatic brain injury, rise in cases of stroke, and advancement in R&D activities for drug development. According to Centers for Disease Control and Prevention, there were an approximately 61,000 traumatic brain injury cases in the U.S. in 2019. Traumatic brain injury is mostly caused by vehicle accidents, or accidental falls. These factors increase the number of traumatic brain injury surgeries. Moreover, in March 2021, B. Braun received Food and Drug Administration approval for the use of Propofol-Lipuro injectable emulsion to maintain anesthesia in patients who require mechanical ventilation intensive care unit during the COVID-19 pandemic.

It provides protection to brain and ultimately reduces the pain of swelling. Thus, increase in use of anesthetics drugs to induce coma in patients who are undergoing various types of surgeries are expected to propel the growth of the market.

Increase in the number of surgical procedures such as cosmetic surgery, brain surgery leads to surge in usage of drugs such as propofol and barbiturate to induce coma in patients are the major factors that drive the global artificial coma/medically induced coma market. Moreover, increase in prevalence of geriatric population significantly contributes toward the market growth. Rise in production of various types of drugs to induce coma acts a key driving force of the global market. Moreover, in June 2019, Fresenius Kabi announced the immediate availability of dexmedetomidine hydrochloride in 0.9% sodium chloride injection, a medication used to induce coma during surgery and other procedures. For instance, in 2020, Medova and the New York School of Regional Anesthesia entered a partnership to introduce Safira injection in the U.S for anesthetic use.

In addition, as per the statistics provided by the American Society of Plastic Surgeons in 2019, approximately 1.8 million cases of cosmetic minimally-invasive surgeries were performed in the U.S. The rise in demand for various anesthetic for surgical procedures being performed. The application of anesthetics in general surgeries is expected to drive the growth of the market. Furthermore, the data provided by Organization for Economic Co-operation and Development, in Germany, total number of 45,307 cases of coronary artery bypass grafting procedures were performed in 2018. Hence, the increasing incidences of emergency surgeries, extensive uses of propofol and barbiturate drugs propels the growth of the market.

Surgery is known as the best cure for various serious types of diseases. The prevalence of cardiovascular diseases in China has been increasing continuously. As per the report published in the Journal of Geriatric Cardiology by Li-Yuan Ma, approximately 290 million patients of cardiovascular disorders in China and approximately 2 in 5 deaths were happened in China due to CVD. Therefore, the rising number of cardiovascular diseases results in increasing number of surgeries that help to boost the growth of the market. Ageing population is at high risk of having cardiovascular diseases, which leads to increasing demand for surgical interventions. Thus, increasing geriatric population is also expected to drive the substantial growth of the market during forecast period.

On the contrary, side effects associated with artificial coma/medically induced coma and risk associated with pregnant women are anticipated to hinder the market growth during the forecast period. Emerging markets & significant R&D to develop efficient drugs, and unmet demand in the under developed & developing countries are projected to provide substantial growth opportunities for key players in artificial coma/medically induced coma market.

The global artificial coma/medically induced coma market is segmented on the basis of drug type, application, distribution channel, and region. By drug type, the market is categorized into propofol and barbiturate. By application, the market is fragmented into status epilepticus, stroke, traumatic brain injury, brain infections, drug overdose, and others. By distribution channel, the market is categorized into hospital pharmacies, drug stores & retail pharmacies and online providers. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the global artificial coma/medically induced coma market are Astrazeneca Plc., B. Braun Melsungen, Baxter Healthcare Corporation, Dr. Reddy's Laboratories, Fresenius SE & CO., Hikma Pharmaceuticals, Pfizer Inc., Piramal Healthcare, Teva Pharmaceuticals Industries Ltd., and Viatris Inc.

KEY BENEFITS FOR STAKEHOLDERS

  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global artificial coma/medically induced coma market to identify the prevailing opportunities.
  • This study presents the competitive landscape of the global market to predict the competitive environment across geographies.
  • Comprehensive analysis of factors that drive and restrict the market growth is provided.
  • Region- & country-wise analysis is provided to understand the market trends and dynamics.

KEY MARKET SEGMENTS

By Drug Type

  • Propofol
  • Barbiturate

By Application

  • Status Epilepticus
  • Stroke
  • Traumatic Brain Injury
  • Brain Infections
  • Drug Overdose
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

KEY MARKET PLAYERS

  • Astrazeneca Plc.
  • B. Braun Melsungen
  • Baxter Healthcare Corporation
  • Dr.Reddy's Laboratories
  • Fresenious SE & CO.
  • Hikma Pharmaceuticals
  • Pfizer Inc.
  • Piramal Healthcare
  • Teva Pharmaceuticals Industries Ltd.
  • Viatris Inc

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top winning strategies
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning, 2020
  • 3.5.Market dynamics
    • 3.5.1.Drivers
      • 3.5.1.1.Escalating demand for the management of pain from geriatric population
      • 3.5.1.2.Increase in number of emergency surgeries
      • 3.5.1.3.Increase in number of drug launch and approvals
      • 3.5.1.4.Rising prevalence of cancer
    • 3.5.2.Restraints
      • 3.5.2.1.Risk associated with the use of anesthetics in pediatric patients and pregnant women
      • 3.5.2.2.Side effects associated with anesthetics
    • 3.5.3.Opportunity
      • 3.5.3.1.Rise in heavy investment in healthcare sector
    • 3.5.4.Impact analysis
  • 3.6.Impact analysis of COVID-19 on the artificial coma/medically induced coma market

CHAPTER 4:ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY TYPE

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Propofol
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by region
    • 4.2.3.Market analysis, by country
  • 4.3.Barbiturate
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast, by region
    • 4.3.3.Market analysis, by country

CHAPTER 5:ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY APPLICATION

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Status Epilepticus
    • 5.2.1.Market size and forecast, by region
    • 5.2.2.Market analysis, by country
  • 5.3.Stroke
    • 5.3.1.Market size and forecast, by region
    • 5.3.2.Market analysis, by country
  • 5.4.Traumatic Brain Injury
    • 5.4.1.Market size and forecast, by region
    • 5.4.2.Market analysis, by country
  • 5.5.Brain Infections
    • 5.5.1.Market size and forecast, by region
    • 5.5.2.Market analysis, by country
  • 5.6.Drug Overdose
    • 5.6.1.Market size and forecast, by region
    • 5.6.2.Market analysis, by country
  • 5.7.Others
    • 5.7.1.Market size and forecast, by region
    • 5.7.2.Market analysis, by country

CHAPTER 6:ARTIFICIAL COMA/MEDICALLY INDUCED COMAMARKET, BY DISTRIBUTION CHANNEL

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Hospital Pharmacies
    • 6.2.1.Market size and forecast, by region
    • 6.2.2.Market analysis, by country
  • 6.3.Drug Stores & Retail Pharmacies
    • 6.3.1.Market size and forecast, by region
    • 6.3.2.Market analysis, by country

CHAPTER 7:ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key market trends, growth factors, and opportunities
    • 7.2.2.North America artificial coma/medically induced coma market, by type
    • 7.2.3.North America artificial coma/medically induced coma market, by Application
    • 7.2.4.North America artificial coma/medically induced coma market, by distribution channel
    • 7.2.5.Market size and forecast, by country
      • 7.2.5.1.U.S.
      • 7.2.5.1.1.U.S. artificial coma/medically induced coma market, by type
      • 7.2.5.1.2.U.S. artificial coma/medically induced coma market, by application
      • 7.2.5.1.3.U.S. artificial coma/medically induced coma market, by distribution channel
      • 7.2.5.2.Canada
      • 7.2.5.2.1.Canada artificial coma/medically induced coma market, by type
      • 7.2.5.2.2.Canada artificial coma/medically induced coma market, by application
      • 7.2.5.2.3.Canada artificial coma/medically induced coma market, by distribution channel
      • 7.2.5.3.Mexico
      • 7.2.5.3.1.Mexico artificial coma/medically induced coma market, by type
      • 7.2.5.3.2.Mexico artificial coma/medically induced coma market, by application
      • 7.2.5.3.3.Mexico artificial coma/medically induced coma market, by distribution channel
  • 7.3.Europe
    • 7.3.1.Key market trends, growth factors, and opportunities
    • 7.3.2.Europe artificial coma/medically induced coma market, by type
    • 7.3.3.Europe artificial coma/medically induced coma market, by application
    • 7.3.4.Europe artificial coma/medically induced coma market, by distribution channel
    • 7.3.5.Market size and forecast, by country
      • 7.3.5.1.Germany
      • 7.3.5.1.1.Germany artificial coma/medically induced coma market, by type
      • 7.3.5.1.2.Germany artificial coma/medically induced coma market, by application
      • 7.3.5.1.3.Germany artificial coma/medically induced coma market, by distribution channel
      • 7.3.5.2.France
      • 7.3.5.2.1.France artificial coma/medically induced coma market, by type
      • 7.3.5.2.2.France artificial coma/medically induced coma market, by application
      • 7.3.5.2.3.France artificial coma/medically induced coma market, by distribution channel
      • 7.3.5.3.UK
      • 7.3.5.3.1.UK artificial coma/medically induced coma market, by type
      • 7.3.5.3.2.UK artificial coma/medically induced coma market, by application
      • 7.3.5.3.3.UK artificial coma/medically induced coma market, by distribution channel

The UK artificial coma/medically induced coma market was valued at $31.19 million in 2020, and is projected to reach $42.95 million by 2030, registering a CAGR of 3.2%. The hospital pharmacies was the highest revenue contributor with $20.60 million in 2020, and is estimated to reach $28.87 million by 2030, registering a CAGR of 3.4%.

      • 7.3.5.4.Italy
      • 7.3.5.4.1.Italy artificial coma/medically induced coma market, by type
      • 7.3.5.4.2.Italy artificial coma/medically induced coma market, by application
      • 7.3.5.4.3.Italy artificial coma/medically induced COMA market, by distribution channel
      • 7.3.5.5.Spain
      • 7.3.5.5.1.Spain artificial coma/medically induced coma market, by type
      • 7.3.5.5.2.Spain artificial coma/medically induced coma market, by application
      • 7.3.5.5.3.Spain artificial coma/medically induced coma market, by distribution channel
      • 7.3.5.6.Rest of Europe
      • 7.3.5.6.1.Rest of Europe artificial coma/medically induced coma market, by type
      • 7.3.5.6.2.Rest of Europe artificial coma/medically induced coma market, by application
      • 7.3.5.6.3.Rest of Europe artificial coma/medically induced coma market, by distribution channel
  • 7.4.Asia-Pacific
    • 7.4.1.Key market trends, growth factors, and opportunities
    • 7.4.2.Asia-Pacific artificial coma/medically induced coma market, by type
    • 7.4.3.Asia-Pacific artificial coma/medically induced coma market, by Application
    • 7.4.4.Asia-Pacific artificial coma/medically induced coma market, by distribution channel
    • 7.4.5.Market size and forecast, by country
      • 7.4.5.1.Japan
      • 7.4.5.1.1.Japan artificial coma/medically induced coma market, by type
      • 7.4.5.1.2.Japan artificial coma/medically induced coma market, by application
      • 7.4.5.1.3.Japan artificial coma/medically induced coma market, by distribution channel
      • 7.4.5.2.China
      • 7.4.5.2.1.China artificial coma/medically induced coma market, by type
      • 7.4.5.2.2.China artificial coma/medically induced coma market, by application
      • 7.4.5.2.3.China artificial coma/medically induced coma market, by distribution channel
      • 7.4.5.3.Australia
      • 7.4.5.3.1.Australia artificial coma/medically induced coma market, by type
      • 7.4.5.3.2.Australia artificial coma/medically induced coma market, by application
      • 7.4.5.3.3.Australia artificial coma/medically induced coma market, by distribution channel
      • 7.4.5.4.India
      • 7.4.5.4.1.India artificial coma/medically induced coma market, by type
      • 7.4.5.4.2.India artificial coma/medically induced coma market, by application
      • 7.4.5.4.3.India artificial coma/medically induced coma market, by distribution channel
      • 7.4.5.5.South Korea
      • 7.4.5.5.1.South Korea artificial coma/medically induced coma market, by type
      • 7.4.5.5.2.South Korea artificial coma/medically induced coma market, by application
      • 7.4.5.5.3.South Korea artificial coma/medically induced coma market, by distribution channel
      • 7.4.5.6.Rest of Asia-Pacific
      • 7.4.5.6.1.Rest of Asia-Pacific artificial coma/medically induced coma market, by type
      • 7.4.5.6.2.Rest of Asia-Pacific artificial coma/medically induced coma market, by application
      • 7.4.5.6.3.Rest of Asia-Pacific artificial coma/medically induced coma market, by distribution channel
  • 7.5.LAMEA
    • 7.5.1.Key market trends, growth factors, and opportunities
    • 7.5.2.LAMEA artificial coma/medically induced coma market, by type
    • 7.5.3.LAMEA artificial coma/medically induced coma market, by application
    • 7.5.4.LAMEA artificial coma/medically induced coma market, by distribution channel
    • 7.5.5.Market size and forecast, by country
      • 7.5.5.1.Brazil
      • 7.5.5.1.1.Brazil artificial coma/medically induced coma market, by type
      • 7.5.5.1.2.Brazil artificial coma/medically induced coma market, by application
      • 7.5.5.1.3.Brazil artificial coma/medically induced coma market, by distribution channel
      • 7.5.5.2.Saudi Arabia
      • 7.5.5.2.1.Saudi Arabia artificial coma/medically induced coma market, by type
      • 7.5.5.2.2.Saudi Arabia artificial coma/medically induced coma market, by application
      • 7.5.5.2.3.Saudi Arabia artificial coma/medically induced coma market, by distribution channel
      • 7.5.5.3.South Africa
      • 7.5.5.3.1.South Africa artificial coma/medically induced coma market, by type
      • 7.5.5.3.2.South Africa artificial coma/medically induced coma market, by application
      • 7.5.5.3.3.South Africa artificial coma/medically induced coma market, by distribution channel
      • 7.5.5.4.Rest of LAMEA
      • 7.5.5.4.1.Rest of LAMEA artificial coma/medically induced coma market, by type
      • 7.5.5.4.2.Rest of LAMEA artificial coma/medically induced coma market, by application
      • 7.5.5.4.3.Rest of LAMEA artificial coma/medically induced coma market, by distribution channel

CHAPTER 8:COMPANY PROFILES

  • 8.1.ASTRAZENECA PLC
    • 8.1.1.Company overview
    • 8.1.2.Company snapshot
    • 8.1.3.Operating business segments
    • 8.1.4.Product portfolio
    • 8.1.5.Business performance
    • 8.1.6.Key strategic moves and developments
  • 8.2.B.BRAUN MELSUNGEN AG
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Operating business segments
    • 8.2.4.Product portfolio
    • 8.2.5.Business performance
  • 8.3.BAXTER INTERNATIONAL INC.
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segments
    • 8.3.4.Product Portfolio
    • 8.3.5.Business performance
  • 8.4.DR. REDDY'S LABORATORY
    • 8.4.1.Company overview
  • 8.5.FRESENIUS SE & CO KGAA
    • 8.5.1.Company Overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segments
    • 8.5.4.Product portfolio
    • 8.5.5.Business performance
    • 8.5.6.Key strategic moves and developments
  • 8.6.HIKMA PHARMACEUTICALS
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Operating business segments
    • 8.6.4.Product portfolio
    • 8.6.5.Business performance
    • 8.6.6.Key strategic moves and developments
  • 8.7.PFIZER INC.
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segments
    • 8.7.4.Product portfolio
    • 8.7.5.Business performance
  • 8.8.PIRAMAL GROUP
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Operating business segments
    • 8.8.4.Product portfolio
    • 8.8.5.Business performance
  • 8.9.TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Operating business segments
    • 8.9.4.Product portfolio
    • 8.9.5.Business performance
  • 8.10.VIATRIS INC. (MYLAN N.V)
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Operating business segments
    • 8.10.4.Product portfolio
    • 8.10.5.Business performance
Back to Top
전화 문의
F A Q